Competing interests
Q-DT: Consulting: Astellas, Bayer, Intuitive Surgical, Janssen, Novartis, Pfizer; Research funding: American Cancer Society, Pfizer Global Medical Grants; Funding/grants: Health Disparity Research Award from the Department of Defense Congressionally Directed Medical Research Program. DJG: Consulting: Bayer, Exelixis, Pfizer, Sanofi, Astellas Pharma, Innocrin Pharma, Bristol Myers Squibb, Genentech, Janssen, Merck Sharp & Dohme, Sumitomo Pharma America, (formerly Myovant Sciences), AstraZeneca, Michael J. Hennessy Associates, Constellation Pharmaceuticals, Physicians’ Education Resource, Propella Therapeutics, RevHealth, Xcures, Novartis, Dendreon, Acerta, Calithera Biosciences. NS: Employment: AUC Specialists and START Cancer; Stock and other ownership interests: Photocure, Tutelix; Consulting/Research: Bayer, Janssen Scientific Affairs, Dendreon, Ferring, Astellas, Amgen, Pfizer, AstraZeneca, Astellas Pharma, Merck, Bristol Myers Squibb/ MDxHealth, Myriad Genetics, CG Oncology, UroGen Pharma, Clarity Pharmaceuticals, Lantheus Medical Imaging, Lilly, Telix Pharmaceuticals, Asieris Pharmaceuticals, Minomic, Novartis, Promaxo, Protara Therapeutics, Fize Medical, Accord Aura Biosciences, Bioprotect, Sumitomo. EV: Nothing to disclose. DO: Grants: AstraZeneca, Bayer, Janssen, Pfizer; Personal fees: AstraZeneca, Bayer, Clovis, Daiichi Sankyo, Janssen, Merck Sharp & Dohme, Pfizer; Non-financial support: Astellas Pharma, AstraZeneca, Bayer, F. Hoffman-LaRoche, Genentech, Ipsen, Janssen, Pfizer. AJPdSG: Invited speaker: Astellas, Bayer, Janssen, AstraZeneca; Advisory board member: Bayer, Janssen. ACdAM: Consulting: Astellas, AstraZeneca, Janssen, Pfizer; Research funding: Janssen, AstraZeneca, MSD, Merck, Nektar Therapeutics; Honoraria: Janssen, Pfizer; Advisory board member: Astellas, Bayer, Janssen, Pfizer. NL: Employment: Bayer. SS: Employment: Bayer. FV: Employment: Bayer. KPH: Nothing to disclose. FS: Consulting: AbbVie, Advanced Accelerator Applications, Astellas Pharma, AstraZeneca/MedImmune, Bayer, GSK, Janssen Oncology, Myovant Sciences, Novartis, Pfizer, Knight Therapeautics, Sanofi, Sumitomo Dainippon Pharma Oncology, Tolmar; Honoraria: AbbVie, Advanced Accelerator Applications, Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, GSK, Janssen Oncology, Knight Therapeutics, Merck, Myovant Sciences, Novartis, Pfizer, Sanofi, Sumitomo Dainippon Pharma Oncology, Tolmar; Research funding to institution: AbbVie, Advanced Accelerator Applications, Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Janssen Oncology, Merck, Novartis, Pfizer, Point Therapeutics, Sanofi.
